Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis.
Tupasi T, Gupta R, Danilovits M, Cirule A, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Gentry LM, Geiter LJ, Wells CD. Tupasi T, et al. Among authors: wells cd. Bull World Health Organ. 2016 Feb 1;94(2):147-52. doi: 10.2471/BLT.15.154997. Epub 2015 Nov 17. Bull World Health Organ. 2016. PMID: 26908964 Free PMC article. Clinical Trial.
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R. von Groote-Bidlingmaier F, et al. Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7. Lancet Respir Med. 2019. PMID: 30630778 Clinical Trial.
Delamanid for multidrug-resistant pulmonary tuberculosis.
Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Gler MT, et al. Among authors: wells cd. N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433. N Engl J Med. 2012. PMID: 22670901 Free article. Clinical Trial.
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD. Skripconoka V, et al. Among authors: wells cd. Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27. Eur Respir J. 2013. PMID: 23018916 Free PMC article.
Delamanid for Extensively Drug-Resistant Tuberculosis.
Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H. Gupta R, et al. Among authors: wells cd. N Engl J Med. 2015 Jul 16;373(3):291-2. doi: 10.1056/NEJMc1415332. N Engl J Med. 2015. PMID: 26176402 Free article. Clinical Trial. No abstract available.
Delamanid in the treatment of multidrug-resistant tuberculosis.
Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ. Gupta R, et al. Among authors: wells cd. Int J Tuberc Lung Dis. 2016 Dec 1;20(12):33-37. doi: 10.5588/ijtld.16.0125. Int J Tuberc Lung Dis. 2016. PMID: 28240570 Review.
Multidrug-resistant tuberculosis management in resource-limited settings.
Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blöndal K, Caminero JA, Cegielski JP, Danilovits M, Espinal MA, Hollo V, Jaramillo E, Leimane V, Mitnick CD, Mukherjee JS, Nunn P, Pasechnikov A, Tupasi T, Wells C, Raviglione MC. Nathanson E, et al. Among authors: wells c. Emerg Infect Dis. 2006 Sep;12(9):1389-97. doi: 10.3201/eid1209.051618. Emerg Infect Dis. 2006. PMID: 17073088 Free PMC article.
138 results